Tissue-resident memory T cells in gastrointestinal tumors: turning immune desert into immune oasis

Liang, Mengjie; Wang, Xingzhou; Cai, Daming; Guan, Wenxian; Shen, Xiaofei

doi:10.3389/fimmu.2023.1119383

Cited by 2 publications

(2 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, when co-cultured with breast cancer cells, it was found that CD8 + CD69 + CD103 + TRM exhibited higher levels of IFNG and tumor necrosis factor-alpha (TNF-α) compared to CD8 + CD69 + CD103 − T cells, further mediating a more significant tumor-killing effect [32]. The augmentation of tumor-resident memory T cells correlated with improved survival outcomes in melanoma patients undergoing immunotherapy [33,34]. In addition, TRM could convert "cold" into "hot" tumors, thereby improving the effectiveness of immunotherapy in gastrointestinal tumors [35].…”

Section: Discussionmentioning

confidence: 99%

Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

Zeng,

Yin,

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Emerging data suggested a favorable outcome in advanced non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD) patients treated by immunotherapy. The objective of this study was to investigate the effectiveness of neoadjuvant immunotherapy among NSCLC with COPD versus NSCLC without COPD and explore the potential mechanistic links. Patients and methods Patients with NSCLC receiving neoadjuvant immunotherapy and surgery at Shanghai Pulmonary Hospital between November 2020 and January 2023 were reviewed. The assessment of neoadjuvant immunotherapy’s effectiveness was conducted based on the major pathologic response (MPR). The gene expression profile was investigated by RNA sequencing data. Immune cell proportions were examined using flow cytometry. The association between gene expression, immune cells, and pathologic response was validated by immunohistochemistry and single-cell data. Results A total of 230 NSCLC patients who received neoadjuvant immunotherapy were analyzed, including 60 (26.1%) with COPD. Multivariate logistic regression demonstrated that COPD was a predictor for MPR after neoadjuvant immunotherapy [odds ratio (OR), 2.490; 95% confidence interval (CI), 1.295–4.912; P = 0.007]. NSCLC with COPD showed a down-regulation of HERV–H LTR-associating protein 2 (HHLA2), which was an immune checkpoint molecule, and the HHLA2low group demonstrated the enrichment of CD8+CD103+ tissue-resident memory T cells (TRM) compared to the HHLA2high group (11.9% vs. 4.2%, P = 0.013). Single-cell analysis revealed TRM enrichment in the MPR group. Similarly, NSCLC with COPD exhibited a higher proportion of CD8+CD103+TRM compared to NSCLC without COPD (11.9% vs. 4.6%, P = 0.040). Conclusions The study identified NSCLC with COPD as a favorable lung cancer type for neoadjuvant immunotherapy, offering a new perspective on the multimodality treatment of this patient population. Down-regulated HHLA2 in NSCLC with COPD might improve the MPR rate to neoadjuvant immunotherapy owing to the enrichment of CD8+CD103+TRM. Trial registration Approval for the collection and utilization of clinical samples was granted by the Ethics Committee of Shanghai Pulmonary Hospital (Approval number: K23-228).

show abstract

Section: Discussionmentioning

confidence: 99%

Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

Zeng,

Yin,

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…The rising incidence and often late-stage diagnosis of these malignancies underscore the urgency of developing effective treatment strategies. Recently, cancer immunotherapy has shown remarkable progress in the treatment of various cancers; however, the role of tissue-resident memory T cells (Trm cells) in gastrointestinal cancers has become a subject of increased interest [ 3 , 4 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Tissue-Resident Memory T Cells in Gastrointestinal Cancers: Prognostic Significance and Therapeutic Implications

Sato,

Meng,

Hara

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Gastrointestinal cancers, which include a variety of esophageal and colorectal malignancies, present a global health challenge and require effective treatment strategies. In the evolving field of cancer immunotherapy, tissue-resident memory T cells (Trm cells) have emerged as important players in the immune response within nonlymphoid tissues. In this review, we summarize the characteristics and functions of Trm cells and discuss their profound implications for patient outcomes in gastrointestinal cancers. Positioned strategically in peripheral tissues, Trm cells have functions beyond immune surveillance, affecting tumor progression, prognosis, and response to immunotherapy. Studies indicate that Trm cells are prognostic markers and correlate positively with enhanced survival. Their presence in the tumor microenvironment has sparked interest in their therapeutic potential, particularly with respect to immune checkpoint inhibitors, which may improve cancer treatment. Understanding how Trm cells work will not only help to prevent cancer spread through effective treatment but will also contribute to disease prevention at early stages as well as vaccine development. The role of Trm cells goes beyond just cancer, and they have potential applications in infectious and autoimmune diseases. This review provides a thorough analysis of Trm cells in gastrointestinal cancers, which may lead to personalized and effective cancer therapies.

show abstract

Tissue-resident memory T cells in gastrointestinal tumors: turning immune desert into immune oasis

Cited by 2 publications

References 139 publications

Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

Tissue-Resident Memory T Cells in Gastrointestinal Cancers: Prognostic Significance and Therapeutic Implications

Contact Info

Product

Resources

About